The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
HIV/AIDS Resource Center for Women
Michelle Lopez Alora Gale Precious Jackson Nina Martinez Gracia Violeta Ross Quiroga Loreen Willenberg  
Michelle Alora Precious Nina Gracia Loreen  

Nevirapine-Containing ART Does Not Reduce Combined Oral Contraceptive Effectiveness

January/February 2013

Nevirapine is associated with a 30% decrease in contraceptive hormone levels in pharmacokinetic (PK) studies. Adequately powered studies have not previously been conducted to assess clinical outcomes, such as ovulation, in women receiving concomitant oral contraception and nevirapine.

At the 3rd International Workshop on HIV and Women, Kavita Nanda from FHI 360 presented findings from a study comparing ovulation rates in women receiving combined oral contraceptives (COCs) with nevirapine-containing ART and COCs alone.

This was a non-randomised clinical trial of HIV positive women aged 18-35 years who had regular menstruation, were sexually active, and had no medical contraindications to COC use. It was conducted in South Africa and Uganda between June 2009 and May 2011.


The study enrolled 196 women receiving nevirapine-containing ART and 207 women currently ineligible (> 350 cells/mm3) as a COC-only control group. All women received COCs containing 30 mg of ethinyl estradiol and 300 mg of norgestrel. The investigators estimated ovulation weekly serum progesterone (>10 nmol/L was considered presumptive evidence of ovulation) in the first two treatment cycles. Participants took COCs for at least one cycle before their ovulation assessment. They were tested for pregnancy monthly for 24 weeks.

Women were a median of 29 years of age; most women were in the normal range for BMI and had been pregnant before.

The investigators found no statistically significant differences in ovulation rates between the two groups: 26% of the ART and 16% of COC-only groups ovulated in the first cycle; 18% of ART and 19% of COC-only ovulated in the second and 11% of ART and 12% of COC-only ovulated in both cycles. The unadjusted odds ratio (OR) for ovulation in the ART group compared with the COC-only group was 1.4 (95% CI 0.85-2.18), p=0.2.

Women receiving COCs at baseline were 62% less likely to ovulate during follow up, OR 0.38 (0.2-0.7), p=0.002. Older age (29-32 years) halved the likelihood of ovulation, OR 0.51 (0.27-0.98), p=0.04.

There were nine pregnancies in each group, giving pregnancy rates of 10 per 100 woman years (95% CI 5-19) for each group. Women who missed three or more pills in a row were 17 times more likely to get pregnant; OR 16.76 (3.15-89.24), p=0.001. Self reported adherence and condom use did not differ between the two groups.

Adverse events were no different between the groups; three were serious but unrelated to the study medication (malaria, cellulitis and fracture), all in COC-only group.


Dr Nanda also gave a good overview of what is important with drug interactions with contraceptives at this meeting.


Nanda K et al. Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness: results from South Africa and Uganda. 3rd International Workshop on HIV & Women, 14-15 January 2013, Toronto, Canada. Oral abstract O_03.

Links to other websites are current at date of posting but not maintained.

More From This Resource Center

Newly Diagnosed? Words of Encouragement from HIV-Positive Women

What Every HIV-Positive Woman Should Know About GYN Care and Prevention

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
See Also
Birth Control Pills

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.

See Also
Newly Diagnosed? Words of Encouragement from HIV-Positive Women
What Did You Expect While You Were Expecting?
HIV Tools You Can Use